News

As October draws to a close, the Contagion® editorial team is recapping the trends and top infectious disease news of the month.

Drug combinations including clofazimine were effective in treating 54% of patients with rapidly growing mycobacterial infections, including 71% whose infections were non-pulmonary, new research found.

Regardless of adherence to severe sepsis and septic shock treatment bundles, seeing an ID specialist within the first 12 hours of treatment was associated with a 40% risk reduction for in-hospital mortality in a new study.

Study authors examined which countries offer PrEP reimbursement, what barriers exist to implementation, and calculated the overall “PrEP gap” for the EU.

An analysis of vaccination data among children born in 2015 and 2016 found high and stable coverage, but highlighted sociodemographic disparities in coverage.

Open Forum Infectious Diseases research highlights incidence and cost burden associated with common infection.

A study of female adolescents at a health clinic in New York City has found the presence of HPV in the oral cavity is not uncommon, but the results also offer support for vaccination.

Artificial intelligence and machine learning are being used to track and predict the movement of infectious diseases. Investigators hope these tools will lead to fewer widespread infections in the future.

RHB-105 is an “all-in-one” fixed-dose oral capsule comprising rifabutin 50 mg, amoxicillin 1000 mg, and omeprazole 40 mg.

New research found enterovirus antibodies in dozens of patients diagnosed with AFM and ruled out other viruses, offering more insight into the cause of the mysterious polio-like illness.

Amidst growing concern about antibiotic resistance, a new class of antibiotics may help in the fight against gram-negative bacteria.

Gepotidacin, a potential first-in-class antibiotic, will be evaluated for the treatment of uUTIs and urogenital gonorrhea in the EAGLE studies.

Study results point toward progress in developing an accessible and effective point-of-care TB test.

Both organizations will invest $100 million to develop and advance candidate gene-based cures for HIV and sickle cell disease to clinical trials within 10 years.

A study by Shikha Garg, MD, MPH, and her team with the US Centers for Disease Control and Prevention boosts the evidence base for the benefit of influenza vaccination.

Comparisons between strains show little crossover between ESBL-E coli in meat and in humans.

Universal screening identifies cases in those who do not consider themselves at risk and helps re-link previously known patients who have fallen out of treatment back to care.

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of October 20, 2019.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

The presence of segmented filamentous bacteria in the gut microbiota could protect against rotavirus infection, according to new research from Georgia State University.

Although use of gowns and gloves in targeted settings may still be helpful in preventing health care-associated infections, contact precaution policies in VA long-term care facilities had no impact on MRSA acquisition.

According to the WHO’s latest Global TB Report, more than 7 million individuals received treatment for the disease in 2018, but funding gaps could stall progress toward ending TB by 2030.

The supplemental new drug application was approved based on results of a phase 3 trial in which IV-to-oral delafloxacin met the primary end point of statistical non-inferiority to moxifloxacin.

A medication that secretes growth hormone is shown to reduce liver fat in an HIV-positive population, and investigators would like to see it used more widely.

What hurdles are companies facing in the pursuit of developing new antibiotics against multidrug-resistant organisms?

Results from a study at a Cincinnati hospital point to the importance of testing at-risk infants for HCV as the opioid crisis impacts prevalence of the infection.

H3N2, a particularly virulent strain of influenza, blew through Australia. Is it coming to the United States this fall and winter?

A new study points to an increased risk for infections in patients with PTSD.

Leaders from the WHO and various impacted countries met to assess the risks of the Ebola outbreak in the Democratic Republic of the Congo and the future of the outbreak response.